JP2020200352A5 - - Google Patents

Download PDF

Info

Publication number
JP2020200352A5
JP2020200352A5 JP2020161995A JP2020161995A JP2020200352A5 JP 2020200352 A5 JP2020200352 A5 JP 2020200352A5 JP 2020161995 A JP2020161995 A JP 2020161995A JP 2020161995 A JP2020161995 A JP 2020161995A JP 2020200352 A5 JP2020200352 A5 JP 2020200352A5
Authority
JP
Japan
Prior art keywords
composition
subject
use according
apoe4
mmse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020161995A
Other languages
English (en)
Japanese (ja)
Other versions
JP7128536B2 (ja
JP2020200352A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020200352A publication Critical patent/JP2020200352A/ja
Publication of JP2020200352A5 publication Critical patent/JP2020200352A5/ja
Priority to JP2022128786A priority Critical patent/JP2022145949A/ja
Application granted granted Critical
Publication of JP7128536B2 publication Critical patent/JP7128536B2/ja
Priority to JP2025023627A priority patent/JP2025065545A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020161995A 2015-09-10 2020-09-28 特定の患者集団において神経変性障害を処置する方法 Active JP7128536B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022128786A JP2022145949A (ja) 2015-09-10 2022-08-12 特定の患者集団において神経変性障害を処置する方法
JP2025023627A JP2025065545A (ja) 2015-09-10 2025-02-17 特定の患者集団において神経変性障害を処置する方法

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US62/216,404 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US62/290,287 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US62/302,027 2016-03-01
US201662365809P 2016-07-22 2016-07-22
US62/365,809 2016-07-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018512564A Division JP6789579B2 (ja) 2015-09-10 2016-09-09 特定の患者集団において神経変性障害を処置する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022128786A Division JP2022145949A (ja) 2015-09-10 2022-08-12 特定の患者集団において神経変性障害を処置する方法

Publications (3)

Publication Number Publication Date
JP2020200352A JP2020200352A (ja) 2020-12-17
JP2020200352A5 true JP2020200352A5 (enExample) 2021-04-30
JP7128536B2 JP7128536B2 (ja) 2022-08-31

Family

ID=58240195

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018512564A Active JP6789579B2 (ja) 2015-09-10 2016-09-09 特定の患者集団において神経変性障害を処置する方法
JP2020161995A Active JP7128536B2 (ja) 2015-09-10 2020-09-28 特定の患者集団において神経変性障害を処置する方法
JP2022128786A Pending JP2022145949A (ja) 2015-09-10 2022-08-12 特定の患者集団において神経変性障害を処置する方法
JP2025023627A Pending JP2025065545A (ja) 2015-09-10 2025-02-17 特定の患者集団において神経変性障害を処置する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018512564A Active JP6789579B2 (ja) 2015-09-10 2016-09-09 特定の患者集団において神経変性障害を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022128786A Pending JP2022145949A (ja) 2015-09-10 2022-08-12 特定の患者集団において神経変性障害を処置する方法
JP2025023627A Pending JP2025065545A (ja) 2015-09-10 2025-02-17 特定の患者集団において神経変性障害を処置する方法

Country Status (21)

Country Link
US (3) US11191742B2 (enExample)
EP (2) EP3347002B1 (enExample)
JP (4) JP6789579B2 (enExample)
KR (2) KR102547164B1 (enExample)
CN (3) CN116712423A (enExample)
AU (1) AU2016319107B2 (enExample)
CA (1) CA2997376C (enExample)
DK (1) DK3347002T3 (enExample)
ES (1) ES2952727T3 (enExample)
FI (1) FI3347002T3 (enExample)
HR (1) HRP20230809T1 (enExample)
HU (1) HUE062511T2 (enExample)
LT (1) LT3347002T (enExample)
MD (1) MD3347002T2 (enExample)
MX (2) MX392677B (enExample)
PL (1) PL3347002T3 (enExample)
PT (1) PT3347002T (enExample)
RS (1) RS64481B1 (enExample)
SI (1) SI3347002T1 (enExample)
SM (1) SMT202300250T1 (enExample)
WO (1) WO2017044840A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE063369T2 (hu) 2014-03-21 2024-01-28 Alzheon Inc Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben
PT3347002T (pt) * 2015-09-10 2023-07-27 Alzheon Inc Tratamento de doença de alzheimer numa população particular de pacientes
CN108623501B (zh) 2017-03-21 2022-04-19 润佳(苏州)医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
CN110003058B (zh) * 2018-01-04 2022-01-25 润佳(苏州)医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
US12083082B2 (en) * 2018-08-01 2024-09-10 Alzheon, Inc. Methods for treating neurodegenerative disorders
US12285400B2 (en) * 2018-08-01 2025-04-29 Alzheon, Inc. Sulfopropanoic acid derivatives for treating neurodegenerative disorders
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳(苏州)医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
BR112021025504A2 (pt) * 2019-06-17 2022-04-26 Alzheon Inc Métodos para tratar distúrbios neurodegenerativos
CN116059192B (zh) 2019-11-13 2024-10-29 润佳(苏州)医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
MX2024007070A (es) * 2021-12-09 2024-08-22 Alzheon Inc Alz-801 para uso en el tratamiento de la enfermedad de alzheimer.
CA3251073A1 (en) * 2022-02-07 2023-08-10 Alzheon Inc ALZ-801 FOR USE IN THE TREATMENT OF A NEUROLOGICAL SYMPTOM ASSOCIATED WITH COVID-19

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
KR100279898B1 (ko) 1992-10-13 2001-04-02 로버트 엘. 타버 알쯔하이머 질환의 검출방법
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
SG145784A1 (en) 2003-08-11 2008-09-29 California Inst Of Techn Microfluidic large scale integration
JP2008535907A (ja) * 2005-04-12 2008-09-04 ニユーロケム(インターナショナル)、リミテッド アミロイド阻害化合物の薬学的製剤
JP5607930B2 (ja) 2006-10-12 2014-10-15 ビーエイチアイ リミテッド パートナーシップ 3−アミノ−1−プロパンスルホン酸を送達するための方法、化合物、組成物および媒体
EP2102165A2 (en) 2006-11-24 2009-09-23 AC Immune S.A. N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
WO2012006329A2 (en) 2010-07-06 2012-01-12 Genomind, Llc Apoe4 and apoj biomarker-based prevention and treatment of dementia
US10449177B2 (en) * 2010-08-19 2019-10-22 Buck Institute For Research On Aging Methods of treating mild cognitive impairment (MCI) and related disorders
WO2013168174A1 (en) * 2012-05-08 2013-11-14 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
EP2994160B1 (en) * 2013-05-06 2019-07-03 Baxalta Incorporated Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
KR20240094017A (ko) 2014-02-08 2024-06-24 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
HUE063369T2 (hu) 2014-03-21 2024-01-28 Alzheon Inc Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben
PT3347002T (pt) * 2015-09-10 2023-07-27 Alzheon Inc Tratamento de doença de alzheimer numa população particular de pacientes

Similar Documents

Publication Publication Date Title
JP2020200352A5 (enExample)
KR102795284B1 (ko) 베타-히드록시부티레이트 및 부탄디올의 s-거울상이성질체 및 이의 사용 방법
Healy et al. An association between recurrent oro‐genital ulceration and non‐steroidal anti‐inflammatory drugs
Marks et al. A new form of long QT syndrome associated with syndactyly
JP6491174B2 (ja) ニタゾキサニドの制御放出医薬配合物
JP2018526407A5 (enExample)
KR20210095973A (ko) 호산구성 식도염의 치료 방법
CN1681486A (zh) 莫达非尼药物剂型
CN109431966B (zh) 依达拉奉药物组合物
FI3347002T3 (fi) Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa
WO2018040989A1 (zh) 依达拉奉与(+)-2-莰醇的舌下用药物组合物
US20200054627A1 (en) Treating Pain In Patients With Hepatic Impairment
US20100035927A1 (en) Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia
JP2017508737A5 (enExample)
Smith et al. Lesch-Nyhan syndrome: a case report
JP2015521647A5 (enExample)
JP2002348240A (ja) 医薬組成物
JP2025111439A (ja) トラピジルを使用した認知障害の治療
CN115607545B (zh) 依达拉奉在自闭症谱系障碍治疗中的应用
EP2184284B1 (en) Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient
US20110301199A1 (en) Compositions and methods for treating myelodysplastic syndrome
CN115040491A (zh) 钾离子竞争性酸阻滞剂和乙酰水杨酸的复方制剂及其制备方法
RU2002115814A (ru) Лечение системной красной волчанки с помощью дегидроэпиандростерона
FI4032530T3 (fi) Pidennetysti vapautuva furatsidiinikoostumus
JP2005516925A5 (enExample)